ClinicalTrials.gg
RecruitingNCT06431490Updated Apr 8, 2026

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

A Phase 1/2 interventional study of TQB2102 for injection in Biliary Tract Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 43 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
50th of 157
102 · median 62
Started
2024
with 23 others
Phase 1/2
24 of 176
11 open now
Primary completion
2027-05
later than 52 of 110 live
Registered
102nd of 176
by date

Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 50th largest by planned enrollment of the 157 interventional ones that give a count, is one of 24 that started in 2024, is one of 24 in phase 1/2, reaches primary completion later than 52 of the 110 other live ones, and was the 102nd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 141 Biliary Tract Neoplasms studies recruiting now, 81 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.

03

Conditions studied

  • Biliary Tract Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years ≤ age ≤75 years; (ECOG) score 0 to 1;
  • Subjects must provide sufficient tumor tissue sample and confirm positivity by central laboratory prior to first dose, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with in situ hybridization (ISH) positive;
  • The main organs function well;
  • Meet the criteria for advanced biliary tract cancer:

    1. Biliary tract carcinoma confirmed by histology or cytology;
    2. Non-operable locally advanced, recurrent and/or disease with at least one according to Evaluation criteria for the efficacy of solid tumors () 1.1 criteria;
    3. Failure of 1-2
  • Women of reproductive age should agree that effective must be used during the study period and for 6 months after the end of the study, and that serum or urine pregnancy tests are negative within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for 6 months after the end of the study period;
  • The subjects voluntarily joined the study, signed the , and the compliance was good.

Exclusion criteria

Exclusion Criteria:

  • Complicated diseases and medical history:

    1. Have had or are currently suffering from other malignant tumors within 3 years before the first medication;
    2. Unmitigated toxic effects higher than grade 1 of (CTCAE) due to any previous treatment;
    3. Major surgical treatment, significant traumatic injury, or long-term unhealed wounds or fractures have been received within 4 weeks prior to initial medication;
    4. Patients with any bleeding or bleeding events ≥CTCAE grade 3 within 4 weeks before the first dose; Aortic/venous thrombosis events, such as cerebrovascular accidents (including ), deep vein thrombosis, and pulmonary embolism, occurred within 6 months prior to initial administration; Treatment with low molecular weight heparin was permitted and antiplatelet drugs were prohibited throughout the study period;
    5. Active viral hepatitis with poor control;
    6. There is a history of active tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia, radiation pneumonia requiring treatment or active pneumonia with clinical symptoms;
    7. Have a history of psychotropic drug abuse and can not quit or have mental disorders;
    8. People who are ready to undergo or have previously received bone marrow transplantation or solid organ transplantation;
    9. Have a history of hepatic encephalopathy;
    10. Currently on or recently used (within 7 days before the start of study treatment) aspirin (>325 mg/ day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;
    11. Subjects with any severe and/or uncontrolled disease.
  • Tumor related and treatment:

    1. For subjects who have received chemotherapy, immunotherapy within 3 weeks before the first dose, radiation therapy or small molecule targeted drugs within 2 weeks, or who are still within the 5 half-lives of the drug (as the shortest time of occurrence), the is calculated from the end time of the last treatment;
    2. Within 2 weeks before the first use of the drug, the treatment of Chinese patent drugs with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions;
    3. Imaging including computed tomography (CT) or magnetic resonance imaging (MRI) shows that the tumor has invaded important blood vessels, or the investigator determines that the tumor is highly likely to invade important blood vessels during the follow-up study period and cause fatal massive bleeding;
    4. Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites that still require repeated drainage;
    5. Obvious biliary obstruction (except for total ≤ 2× (ULN) after endoscopic stent placement and percutaneous transhepatic biliary drainage);
    6. Known spinal cord compression, cancerous meningitis, with symptoms of , or symptoms controlled for less than 4 weeks.
  • Research treatment related:

    1. Known allergy to study drug ;
    2. Have previously received anti- therapy drugs (only for the second stage, the first stage is not limited);
    3. Patients who require , systemic, or absorbable topical hormone therapy for immunosuppressive purposes and who continue to use it for 7 days prior to initial administration (except for \<10 mg per day of prednisone or other therapeutic hormones).
    4. Participants who participated in and used other anti-tumor clinical trials within 4 weeks before the first medication.
    5. According to the judgment of the researcher, there is a situation that seriously endangers the safety of the subjects or affects the completion of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    TQB2102 for injection

    Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 6/8 cycles.

    Drug: TQB2102 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE) and serious adverse events (SAE)

    Any adverse medical event that occurred from the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy (whichever came first).

    Time frame: From the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy

  2. Phase II Recommended Dose (RP2D)

    Phase II Recommended Dose (RP2D)

    Time frame: Baseline up to 24 weeks

Secondary outcomes

  1. Objective response rate (ORR)

    The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.

    Time frame: Baseline up to 36 weeks

  2. Progression-free survival (PFS)

    The time between first medication and first disease progression or death from any cause.

    Time frame: Baseline up to 36 weeks

  3. Disease control rate (DCR)

    The first assessment was complete response, partial response, and time to disease stabilization.

    Time frame: Baseline up to 36 weeks

  4. Disease response time (DOR)

    First assessed as complete or partial response to first disease progression or time of death from all causes.

    Time frame: Baseline up to 36 weeks

  5. Overall survival (OS)

    Time from first use to death from any cause

    Time frame: Baseline up to 36 weeks

07

Study locations

2 of 43 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for May 2027, 34 months after the start.

Of 48 phase 1/2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 68. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 28, 2024
StartActual
Jul 22, 2024
Primary completionEst.
May 2027
CompletionEst.
Dec 2029
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06431490
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Jul 22, 2024
Primary completion
May 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Apr 8, 2026

Study contacts

Feng Shen, Doctor
Contact
shenfengehbh@sina.com
13901651428
Jun Zhou, Doctor
Contact
13366152815@126.com
13366152815

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion